Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells

Blood

Volumn 87, Issue 3, 1996, Pages 1064-1074

  Ehinger, Mats ^a   Bergh, Gösta ^b   Olofsson, Tor ^b   Baldetorp, Bo ^b   Olsson, Inge ^b   Gullberg, Urban ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CD11B ANTIGEN; CD14 ANTIGEN; DNA FRAGMENT; GLYCOPROTEIN P 15095; MEMBRANE ANTIGEN; NITROBLUE TETRAZOLIUM; PROTEIN P53; RETINOIC ACID; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; FLOW CYTOMETRY; GROWTH RATE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030042825     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.1064.bloodjournal8731064     Document Type: Article

References (58)

1. Rabbits TH: Chromosomal translocations in human cancer. Nature 372:143, 1994
2. Liebermann DA, Hoffman B: Differentiation primary response genes and proto-oncgenes as positive and negative regulators of terminal hematopoietic cell differentiation. Stem Cells 12:352, 1994
3. Hollstein M, Sidrartsky D, Vogelstein B, Harris CC: p53-mutations in human cancers. Science 253:49, 1991
4. Lane DP, Benchimol S: p53: Oncogene or anti-oncogene? Genes Dev 4:1, 1990
5. Lane DP, Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261, 1979
6. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1B-58Kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54Kd cellular protein in transformed cells. Cell 28:387, 1982
7. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76, 1990
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237, 1992
9. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262, 1992
10. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166, 1990
11. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912, 1990
12. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772, 1990
13. Johnson P, Gray D, Mowat M, and Benchimol S: Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol 11:1, 1991
14. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA-damage. Cancer Res 51:6304, 1991
15. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491, 1992
16. Kastan MB, Zhan Q, El-Deiry WS, Carrie F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587, 1992
17. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
18. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
19. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345, 1991
20. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence J-J, May P, Oren M: p53-mediated cell-death: Relationship to cell cycle control. Mol Cell Biol 13:1415, 1993
21. Shaulsky G, Goldfinger N, Peled A, Rotter V: Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci USA 88:8982, 1991
22. Feinstein E, Gale RP, Reed J, Canaani E: Expression of normal p53 gene induces differentiation of K562 cells. Oncogene 7:1853, 1992
23. Johnson P, Chung S, Benchimol S: Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol 13:1456, 1993
24. Soddu S, Blandino G, Citro G, Scardigli R, Piaggio G, Ferber A, Calabretta B, Sacchi A: Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 83:2230, 1994
25. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CJ, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215, 1992
26. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME: Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9:3389, 1994
27. Jiang H, Lin J, Su Z, Collart FR, Huberman E, Fisher PB: Induction of differentiation in human promyelocytic HL-60 cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397, 1994
28. Ahuja H, Bar Eli E, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A, Cline M: The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87:2042, 1991
29. Fenaux P, Jonveaux P, Quiquandon I, Laï JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78:1652, 1991
30. Nakai H, Misawa S, Togushida J, Yandell DW, Ishizaki K: Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 52:6588, 1992
31. Galdano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
32. Jonveaux P, Fenaux P, Quiquandon I, Pignon JM, Laï JL, Loucheux-Lefebvre MH, Goossens M, Bauters F, Berger R: Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 6:2243, 1991
33. Preudhomme C, Quesnel B, Vachee A, Lepelley P, Collyn-D'Hoog M, Wattel E, Fenaux P: Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia 7:1291, 1993
34. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391, 1994
35. Imamura J, Miyoshi I, Koeffler P: p53 in hematologic malignancies. Blood 84:2412, 1994
36. Schottelius A, Brennscheidt U, Ludwig WD, Mertelsmann RH, Herrmann F, Lübbert M: Mechanisms of p53 alteration in acute leukemias. Leukemia 8:1673, 1994
37. Sucai B, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JM: p53 in chronic myeloid leukemia cell lines. Leukemia 6:839, 1992
38. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H: Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79:2378, 1992
39. Breitman TR, Selonick SE, Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936, 1980
40. Olsson I, Breitman TR: Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3′:5′-monophosphate-inducing agents. Cancer Res 42:3924, 1982
41. Olsson I, Gullberg U, Ivhed I, Nilsson K: Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1,25-Dihydroxycholecalciferol. Cancer Res 43:5862, 1983
42. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY: Use of ATRA in the treatment of acute promyelocyte leukemia. Blood 72.567, 1988
43. Ehinger M, Nilsson E, Persson AM, Olsson I, Gullberg U: Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. Cell Growth Differ 6:9, 1995
44. Eliyahu D, Michalovitz D, Oren M: Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316:158, 1985
45. Michalovitz D, Halevy O, Oren M: Conditional inhibition of transformation and cell proliferation by temperature-sensitive mutant of p53. Cell 62:621, 1990
46. Sundström C, Nilsson K: Establishment and characterization of a human histiocytic cell-line (U-937). Int J Cancer 7:565, 1976
47. Harlow E, Crawford LV, Pim DC, Williamson NM: Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol 39:861, 1981
48. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimetylsulfoxide. J Exp Med 149:969, 1979
49. Baldetorp B, Fernö M, Fallenius A, Fallenius-Vecchi G, Idvall I, Olsson H, Sigurdsson H, Åkerman M, Killander D: Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 13:577, 1992
50. Baldetorp B, Dahlberg M, Holst U, Lindgren G: Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. Cytometry 10:695, 1989
51. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13:795, 1992
52. Todd RF, Nadler LM, Schlossman SF: Antigens on human monocytes identified by monoclonal antibodies. J Immunol 126:1435, 1981
53. Todd RF, Schlossman SF: Analysis of antigenic determinants on human monocytes and macrophages. Blood 59:775, 1982
54. Conrad DH: FceRII/CD23: The low affinity receptor for IgE. Annu Rev Immunol 8:623, 1990
55. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of Lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431, 1990
56. Öberg F, Botling J, Nilsson K: Functional antagonism between vitamin D3 and Retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. J Immunol 150:3487, 1993
57. Carlos TM, Harlan JM: Leukocyte-Endothelial adhesion molecules. Blood 84:2068, 1994
58. Selvakumaran M, Reed JC, Liebermann D, Hoffman B: Progression of the myeloid differentiation program is dominant to transforming growth factor-β1-induced apoptosis in M1 myeloid leukemic cells. Blood 84:1036, 1994